Efficacy of a Novel Formulation of Betamethasone Dipropionate 0.05% Spray Versus Augmented Betamethasone Dipropionate 0.05% Lotion In Patients >= 18 Years of Age with Moderate Plaque Psoriasis: A Pooled Analysis

Main Article Content

Linda Stein Gold MD
Henry Ford Health System, Detroit, MI

Jonathan S. Weiss MD
Georgia Dermatology Partners and Gwinnett Clinical Research Center, Inc., Snellville, GA

Joseph F. Fowler MD
University of Louisville, Louisville, KY

Adelaide A. Hebert MD
UTHealth McGovern Medical School, Houston, TX

Adelaide A. Hebert MD
UTHealth McGovern Medical School, Houston, TX

Jeffrey Sugarman MD
Redwood Dermatology Research, Santa Rosa, CA

Keywords

Plaque Psoriasis, Betamethasone

References

1. Kircik L, Okumu F, Kandavilli S, Sugarman J. Rational Vehicle Design Ensures Targeted Cutaneous Steroid Delivery. J Clin Aesthetic Dermatol 2017;10(2):12-19.

2. Fowler JF, Hebert AA, Sugarman J. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis. J Drugs Dermatol 2016;15(2):154-162.

3. Sidgiddi S, Pakunlu RI, Allenby K. Efficacy, Safety, and Potency of Betamethasone Dipropionate Spray 0.05%: A Treatment for Adults with Mild-to-moderate Plaque Psoriasis. J Clin Aesthetic Dermatol 2018;11(4):14-22.

4. Stein Gold L, Jackson JM, Knuckles MLF, Weiss JS. Improvement in Extensive Moderate Plaque Psoriasis with a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05%. J Drugs Dermatol 2016;15(3):334-342.

Article Sidebar

Poster PDF
Published
May 20, 2023
DOI https://doi.org/10.25251/skin.7.supp.203

Article Details

How to Cite
[1]
Stein Gold MD, L., Weiss MD, J.S., Fowler MD, J.F., Hebert MD, A.A., Hebert MD, A.A. and Sugarman MD, J. 2023. Efficacy of a Novel Formulation of Betamethasone Dipropionate 0.05% Spray Versus Augmented Betamethasone Dipropionate 0.05% Lotion In Patients >= 18 Years of Age with Moderate Plaque Psoriasis: A Pooled Analysis. SKIN The Journal of Cutaneous Medicine. 7, 3 (May 2023), s203. DOI:https://doi.org/10.25251/skin.7.supp.203.
Issue
Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Section
Posters from 2023 WCH and WCM Conferences: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.